Myung In Pharm

KSC:317450 · KR7317450005

PharmaceuticalsSmall

360

Medium confidence — indicative

Value65

Profit price24

Cash yield51

Owner Earnings Yield100

Dividend Yield1

Sales & asset price58

Price/Sales18

EV / Gross Profit100

Price/Book55

Quality61

Returns on capital84

Return on Capital91

Cash Return on Capital76

Return on Equity86

Profit margins71

EBIT Margin98

Gross Profitability43

Cash backing42

Cash Conversion34

Accruals5

Owner Earnings Margin88

Growth36

Sales growth43

Profit growth36

Profit Growth39

Long-Term EPS Growth44

Owner Earnings Growth26

Reinvestment90

Price momentum10

Safety70

Debt load97

Debt serviceability68

Refinancing36

Debt Payback100

Liquidity94

Sentiment48

Analyst ratings—

Expectations trend—

Market mood59

Value Creation12/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Myung In Pharm clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeKOSE

Websitemyunginph.co.kr

ISINKR7317450005

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

PsychiatryGastroenterologyNeurologyPain ManagementCentral Nervous SystemInflammationCardiovascular

Description

Analysis

Middle-of-the-road

Myung In Pharmaceutical LTD. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is attractive. You pay 9.5× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is tepid and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Myung In Pharm with its peers

Samsung Pharm

KSC:001360

—

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Reyon Pharmaceutical

KSC:102460

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Samil Pharmaceutical

KSC:000520

CountrySouth Korea

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Shinhung

KSC:004080

CountrySouth Korea

IndustryHealth Care Equipment & Supplies

SizeSmall

Full Stock Analysis →

PharmaEssentia

TAI:6446

CountryTaiwan

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Pyridam Farma

JKT:PYFA

CountrySingapore

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →